Aratana Therapeutics, a Kansas City, Kansas-based newly-formed company focused on the development of innovative therapies for the animal health industry, has closed a $20m Series A financing.
The round was led by MPM Capital and Avalon Ventures, with participation from the the Kansas Bioscience Authority.
In conjunction with the transaction, Dr. Steven St. Peter, Managing Director at MPM Capital, and Jay Lichter, Managing Director at Avalon Ventures, will join the company’s board of directors.
The board will also include Ron Meeusen, Founder of Cultivian Ventures as well as Dr. Linda Rhodes, founder and vice-president of clinical development at AlcheraBio, an entrepreneurial contract research organization devoted to helping major animal health companies develop new drugs, who will join Aratana as CEO in February 2011.
Dr. David Rosen is President and Founder of the company.